Your search for oral corticosteroids returned 36 results

Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.

Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.

Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.

High doses of inhaled corticosteroids were associated with lower levels of eosinophils, which may interfere with the recommendation of some monoclonal antibodies in asthma treatment.

Oral contraceptive use in women of reproductive age may increase the risk for lifetime asthma.

Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.

Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.

The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.

Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.